Sharemaestro Newsreel

Armistice Capital (RPID) discloses 3.33M-share position in Rapid Micro Biosystems

Armistice Capital, LLC and Steven Boyd have disclosed a 7.29% stake in Rapid Micro Biosystems, Inc. (RPID), amounting to 3,328,000 shares of Class A common stock. All voting and dispositive power over these shares is shared, with Armistice Capital acting as the investment manager …

Aveanna Healthcare (NASDAQ:AVAH) Shares Gap Up Following Better-Than-Expected Earnings

Aveanna Healthcare (AVAH) shares gapped up after reporting better-than-expected earnings, with revenue rising 13.7% year over year to $670.5 million and adjusted EPS of $0.22, surpassing analyst estimates. The company also raised its 2026 guidance, projecting revenue above $2.68 billion and adjusted EBITDA above …

TuHURA Biosciences, Inc. - Common Stock (HURA) Stock Price, News, Quote & History

This article provides a comprehensive overview of TuHURA Biosciences, Inc. (HURA) stock, including its current price, market data, and recent news. It highlights the company's focus on advancing biotechnology solutions, particularly in developing therapies and diagnostic tools. The news section features updates on their …

Mobia Medical, Inc. - Common Stock MOBI

Mobia Medical, Inc. (NASDAQ:MOBI) reported strong second-quarter results with revenue reaching $13.5 million, marking a 102% increase year-over-year. This growth is attributed to the expanded adoption of its Vivistim paired vagus nerve stimulation therapy within stroke-care programs.

Heartflow (NASDAQ:HTFL) Shares Gap Up Following Better-Than-Expected Earnings

Heartflow (NASDAQ:HTFL) shares gapped up after reporting better-than-expected earnings, with an adjusted EPS of $(0.07) against estimates of $(0.22) and quarterly revenue of $64.08 million, up 47.7% year over year. The stock opened significantly higher at $39.06 and traded near $41.07, surpassing the analyst …

Heartflow Inc stock hits all-time high at 41.25 USD

Heartflow Inc. stock reached an all-time high of $41.25, reflecting strong investor confidence and recent market momentum, despite InvestingPro's analysis suggesting it may be overvalued. The company reported better-than-expected Q2 2026 results with significant revenue growth, though it remains unprofitable. Stifel raised its price …

Armistice Capital reports 9.99% ownership of Tenon Medical (TNON) through Master Fund

Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in Tenon Medical, Inc. (TNON) through Armistice Capital Master Fund Ltd. This ownership, totaling 54,554 shares, grants them shared voting and dispositive power. The filing specifies that the Master Fund retains …

Femasys (FEMY) gains Rosalind-linked holder with potential 9.99% equity stake

Investment entities affiliated with Rosalind Advisors Inc. have reported a potential beneficial ownership of up to 9.99% in Femasys Inc. (FEMY) common shares. This stake includes 723,377 common shares and an additional 3,964,123 shares issuable upon warrant exercise, though blocker provisions cap the effective …

Quince Therapeutics Q2 EPS of $(12.31) beats $(26.32) estimate

Quince Therapeutics (NASDAQ: QNCX) significantly beat Q2 2026 EPS estimates with a loss of $(12.31) against a consensus of $(26.32), marking an 81.9% improvement year-over-year. The company completed its acquisition of Orphai Therapeutics and raised $115 million in a private placement, strengthening its cash …

CLASS ACTION DEADLINE MONDAY NIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

Faruqi & Faruqi, LLP is reminding Embecta (EMBC) investors of the August 17, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Embecta made misleading statements regarding its financial guidance, particularly concerning its pen needle …

ImmuCell Q2 2026 slides: revenue gains offset by margin pressure

ImmuCell (NASDAQ:ICCC) reported mixed Q2 2026 results, with product sales up 11.5% to $7.2 million, but gross margin significantly compressed from 43.7% to 33.9%. Despite a tripling of net income to $1.8 million largely due to a $2 million legal settlement, the stock dropped …

ImmuCell Corporation - Common Stock ICCC

ImmuCell Corporation (ICCC) is a biotechnology company focused on veterinary products, particularly for enhancing immune health in livestock. The company's stock recently traded at $10.20, down 6.47%, and has a market cap of $78.93 million. Recent news highlights include Q2 2026 earnings results, increased …

Solas Capital Management (FENC) reports 1.89M Fennec shares, a 5.4% ownership stake

Solas Capital Management, LLC and Frederick Tucker Golden have reported beneficial ownership of 1,889,366 common shares of Fennec Pharmaceuticals Inc. (FENC), representing a 5.4% stake in the company. This disclosure was made via a SCHEDULE 13G/A filing. The ownership is held through a private …

Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position

Woodline Partners LP has reported an 8.1% beneficial ownership stake in Zevra Therapeutics, Inc. (ZVRA), amounting to 4,785,771 shares. This disclosure, made via an amended Schedule 13G, indicates that Woodline Partners has sole voting and dispositive power over these shares. The ownership percentage is …

T. Rowe Price (RVTY) reports 16.4% Revvity stake, 18.3M shares under control

T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 18,269,089 shares of Revvity Inc. common stock, which accounts for 16.4% of the outstanding class. The firm holds sole voting power over 17,089,376 shares and sole dispositive power over all 18,269,089 shares. …

Bristol Myers Squibb stock gains support from new multiple myeloma approval and raised earnings fore

Woodline Partners discloses 8.1% CalciMedica (CALC) stake and sole voting power

Woodline Partners LP has reported a beneficial ownership of 8.1% in CalciMedica, Inc., totaling 2,489,729 shares of common stock. The investment firm, acting as an adviser to Woodline Master Fund LP, holds sole voting and dispositive power over these shares. This disclosure, made via …

GT Biopharma Q2 Results: Net Loss Falls To $4.5 Million

GT Biopharma (NASDAQ: GTBP) reported a Q2 2026 net loss of $4.5 million, a significant improvement from the $30.2 million loss in Q2 2025, primarily due to the absence of a non-recurring $28.7 million Greenshoe liability from the prior year. However, operational losses widened …

Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.56, Implies 16% Upside

Alto Neuroscience, Inc. (ANRO) has seen its average 12-month price target increased to $37.56 by 9 analysts, suggesting a 16% potential upside from its August 13 closing price. The consensus rating for the stock remains a "Buy" from 11 analysts.

Armistice Capital (TMCI) discloses 6.36M-share Treace Medical ownership stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership stake of 6,364,000 shares in Treace Medical Concepts, Inc. (TMCI), representing 9.79% of the outstanding common stock. This ownership is held directly by Armistice Capital Master Fund Ltd., with Armistice Capital serving as …

Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake

T. Rowe Price Investment Management, Inc. has reported an 11.6% ownership stake in Cabaletta Bio (CABA) common stock, amounting to 18,869,907 shares. The firm holds sole voting power over 18,776,448 shares and sole dispositive power over all 18,869,907 shares, explicitly denying beneficial ownership despite …

GeoVax Labs (GOVX): Armistice Capital and Steven Boyd disclose 4.99% stake

Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in GeoVax Labs, Inc. (GOVX), as detailed in a recent SCHEDULE 13G/A SEC filing. This represents 387,038 shares of common stock with shared voting and dispositive power, as of June 30, …

bioAffinity Technologies prices $4M private placement offering

bioAffinity Technologies (NASDAQ:BIAF) has announced a private placement offering aiming to raise approximately $4.0 million. The company will sell 8,462,027 shares of common stock or pre-funded warrants, alongside warrants to purchase up to 16,924,054 shares, to an institutional investor. The offering is expected to …

T. Rowe Price Associates (DGX) discloses 5.43M Quest Diagnostics shares in 13G/A

T. Rowe Price Associates, Inc. filed an amended Schedule 13G, reporting a beneficial ownership of 5,428,244 shares, or 4.9% of Quest Diagnostics Inc. common stock. The firm holds sole voting power over 5,321,387 shares and sole dispositive power over all 5,428,244 shares, while explicitly …

T. Rowe Price Associates (RVTY) discloses 5.0% beneficial stake in Revvity

T. Rowe Price Associates has filed an amended Schedule 13G, disclosing a 5.0% beneficial ownership stake in Revvity Inc (RVTY) as of June 30, 2026. This amounts to 5,526,874 shares, with T. Rowe Price Associates holding sole voting power over 5,508,363 shares and sole …

Lifeward Ltd. 2026: Revenue $6.62M, Net income ($11.52M), EPS ($4.12) — 10-Q Summary

Lifeward Ltd. reported its 2026 quarterly results, showing a 15.7% year-over-year revenue increase to $6.62 million, driven by higher AlterG shipments and stronger ReWalk sales. Despite the revenue growth, the company recorded a net loss of ($11.52 million) and diluted loss per share of …

Smith & Nephew GAAP EPS of $0.36, revenue of $1.6B

* Smith & Nephew press release [https://seekingalpha.com/filing/309951347] (SNN [https://seekingalpha.com/symbol/SNN]): Q2 GAAP EPS of $0.36. * Revenue of $1.6B (+3.2% Y/Y). * Trading profit for the first half reached $566M, an 8.10% increase year-over-year, expanding the trading profit margin by 60 bps to 18.30%. * …

Armistice Capital (KYNB) discloses 400,000-share, 9.88% Kyntra Bio position

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 400,000 shares of Kyntra Bio, Inc. common stock, which represents 9.88% of the class. Both parties share voting and dispositive power over these shares, held directly by Armistice Capital Master Fund Ltd. …

Lifeward (LFWD) Reports Q2 Loss, Misses Revenue Estimates

Armistice Capital (ICCM) reports 300,332 IceCure Medical shares under shared control

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 300,332 ordinary shares of IceCure Medical Ltd. (ICCM), representing 9.99% of the class, through a Schedule 13G SEC filing. These shares are held with shared voting and dispositive power. Armistice Capital acts as …

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down on Disappointing Earnings

Is Privia Health Group (PRVA) A Bargain As Earnings Growth And Guidance Improve?

Alumis (NASDAQ:ALMS) Shares Gap Down After Earnings Miss

Alumis Inc. (NASDAQ:ALMS) experienced a significant share price drop after reporting disappointing earnings, missing both revenue and EPS consensus estimates. Despite the poor financial results and insider selling, analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and a target price of …

Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings

Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares

Armistice Capital discloses 4.99% VVOS position in Vivos Therapeutics (VVOS)